menu
    • menu
    [{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Sirolimus","moa":"T lymphocyte","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Vascular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vascular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Vascular Therapies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vascular Therapies \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Vascular Therapies

    Menu

    Vascular Therapies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vascular Therapies

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Vascular Therapies

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vascular Therapies Completes Enrollment in Phase III ACCESS 2 Sirolimus Study

                            Details : Sirogen (sirolimus) for the surgical creation of arteriovenous (AV) fistula in patients requiring hemodialysis vascular access is being evaluated for Chronic Kidney Disease.

                            Brand Name : Sirogen

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 05, 2024

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vascular Therapies

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Vascular Therapies

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $17.3 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Vascular Therapies Completes Upsized $17.3 Million Private Financing

                            Details : Vascular Therapies plans to use the proceeds to further advance Sirogen, a proprietary sirolimus formulation for intraoperative, local, perivascular drug delivery.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 28, 2020

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $17.3 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth